PMVP
PMV Pharmaceuticals, Inc.
$1.09
-2.68%
$58.1M
No data for this timeframe.
Vol
Market Cap$58.1M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders4 funds
Inst. Value$4.0M
Inst. Activity3 buys / 0 sells
SEC Reports3
Press Releases1
Recent Activity
Jun 4, 2026
Insider
Stelzer Laurie sold 42,000 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
LEVINE ARNOLD J sold 42,000 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
Gallagher Carol Giltner sold 42,000 shares
Director @ $0.00 ($0.00)
May 12, 2026
SEC
PMV Pharma reported Q1 2026 EPS of -$0.34, beating consensus -$0.39 by 12.8%. The company also announced FDA Orphan Drug
PRESS-RELEASE — Impact 5/10
May 12, 2026
SEC
PMV Pharma reported Q1 2026 net loss per share of -$0.34, in line with the year-ago period and beating consensus estimat
8-K — Impact 3/10
Apr 22, 2026
SEC
PMV Pharmaceuticals is holding its annual shareholder meeting to elect directors and approve executive compensation. The
DEFA14A — Impact 3/10
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
706,061 shares ($882.6K)
Inst.
BANK OF AMERICA CORP — ADD
240,138 shares ($300.2K)
Price Targets
$4.33
+312.7% upside
Strong Buy
Current $1.05
Low $4.00
Median $4.00
High $5.00
3 analysts
$4.00
$5.00
Analyst Ratings
3Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.40 ▲ +4.2% | $-0.41 — $-0.38 | 2% YoY | 3 |
| Next Q | $-0.35 ▲ +7.6% | $-0.40 — $-0.27 | 12% YoY | 3 |
| Current FY | $-1.51 ▲ +5.0% | $-1.54 — $-1.49 | -2% YoY | 2 |
| Next FY | $-1.09 ▲ +0.9% | $-1.19 — $-0.94 | 28% YoY | 3 |
Latest Reports
BULLISH
PRESS-RELEASE
5/10
PMV Pharma reported Q1 2026 EPS of -$0.34, beating consensus -$0.39 by 12.8%. The company also announced FDA Orphan Drug
May 12, 2026
NEUTRAL
8-K
3/10
PMV Pharma reported Q1 2026 net loss per share of -$0.34, in line with the year-ago period and beating consensus estimat
May 12, 2026
MIXED
Press
6/10
PMV Pharmaceuticals reported financial results for 2025, highlighted by advancing its lead drug rezatapopt in the Phase
Mar 6, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $2.7M | — |
| TWO SIGMA INVESTMENTS, LP | $882.6K | DOUBLED |
| BANK OF AMERICA CORP | $300.2K | ADD |
| MORGAN STANLEY | $123.6K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Stelzer Laurie | A | $0.00 |
| Jun 4, 2026 | LEVINE ARNOLD | A | $0.00 |
| Jun 4, 2026 | Gallagher Carol | A | $0.00 |
| Jun 4, 2026 | Gallagher Carol | G | $0.00 |
| Jun 4, 2026 | FLOWERS KIRSTEN | A | $0.00 |
4 institutional holders with $4.0M total value (3,215,384 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, BANK. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,170,310 | $2.7M | 67.5% | — |
| 2 | TWO SIGMA INVESTMENTS, LP | 706,061 | $882.6K | 22.0% | DOUBLED +161.9% |
| 3 | BANK OF AMERICA CORP /DE/ | 240,138 | $300.2K | 7.5% | ADD +47.8% |
| 4 | MORGAN STANLEY | 98,875 | $123.6K | 3.1% | DOUBLED +205.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 269,621 | 706,061 | +161.9% | $882.6K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 162,496 | 240,138 | +47.8% | $300.2K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 32,395 | 98,875 | +205.2% | $123.6K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 29,147 | 162,496 | +457.5% | $227.5K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 122,310 | 1,551 | -98.7% | $2.2K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | EXIT | 10,000 | 0 | -100.0% | $0.00 | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 506,986 | 353,227 | -30.3% | $385.0K | 2025-Q1 |
| UBS Group AG | TRIM | 275,464 | 152,283 | -44.7% | $166.0K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 41,763 | 28,066 | -32.8% | $30.6K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 108,788 | 15,920 | -85.4% | $17.4K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | NEW | — | 10,000 | — | $10.9K | 2025-Q1 |
| FMR LLC | TRIM | 1,005 | 315 | -68.7% | $343.00 | 2025-Q1 |
| UBS Group AG | ADD | 178,866 | 275,464 | +54.0% | $416.0K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 1,060,396 | 108,788 | -89.7% | $164.3K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 59,421 | 41,763 | -29.7% | $63.1K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 119,237 | 59,421 | -50.2% | $88.5K | 2024-Q3 |
9 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Stelzer Laurie | Director | A | 42,000 | $0.00 | $0.00 |
| Jun 4, 2026 | LEVINE ARNOLD J | Director | A | 42,000 | $0.00 | $0.00 |
| Jun 4, 2026 | Gallagher Carol Giltner | Director | A | 42,000 | $0.00 | $0.00 |
| Jun 4, 2026 | Gallagher Carol Giltner | Director | G | 42,000 | $0.00 | $0.00 |
| Jun 4, 2026 | FLOWERS KIRSTEN | Director | A | 42,000 | $0.00 | $0.00 |
| Jun 4, 2026 | BAUM CHARLES M | Director | A | 42,000 | $0.00 | $0.00 |
| Mar 5, 2026 | Mack David Henry | President and CEO | A | 744,960 | $0.00 | $0.00 |
| Mar 5, 2026 | Jalota Deepika | Chief Development Officer | A | 303,310 | $0.00 | $0.00 |
| Mar 5, 2026 | Ticktin Robert | General Counsel & COO | A | 319,270 | $0.00 | $0.00 |
| Mar 5, 2026 | Carulli Michael | Chief Financial Officer | A | 240,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 3.7/10.
BULLISH
PRESS-RELEASE
5/10
PMV Pharma reported Q1 2026 EPS of -$0.34, beating consensus -$0.39 by 12.8%. The company also annou
May 12, 2026
NEUTRAL
8-K
3/10
PMV Pharma reported Q1 2026 net loss per share of -$0.34, in line with the year-ago period and beati
May 12, 2026
NEUTRAL
DEFA14A
3/10
PMV Pharmaceuticals is holding its annual shareholder meeting to elect directors and approve executi
Apr 22, 2026
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 3 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$4.33 mean target
+312.7% upside
Strong Buy (3.00)
$4.00 Low
$5.00 High
| Metric | Value |
|---|---|
| Current Price | $1.05 |
| Target Low | $4.00 |
| Target Mean | $4.33 |
| Target Median | $4.00 |
| Target High | $5.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.40 | $-0.41 | $-0.38 | 2.4% | +4.2% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.35 | $-0.40 | $-0.27 | 11.7% | +7.6% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-1.51 | $-1.54 | $-1.49 | -2.4% | +5.0% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-1.09 | $-1.19 | $-0.94 | 27.8% | +0.9% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.400 | |
| 7d ago | $-0.417 | +0.017 |
| 30d ago | $-0.417 | +0.017 |
| 60d ago | $-0.417 | +0.017 |
| 90d ago | $-0.360 | -0.040 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings
PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
<p align="justify">PRINCETON, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a prec
May 11, 2026
earnings_calendar
PMVP Q1 2026 Earnings Scheduled — 2026-05-11
May 8, 2026
earnings_calendar
PMVP Q1 2026 Earnings Scheduled — 2026-05-08
May 7, 2026
earnings_calendar
PMVP Q1 2026 Earnings Scheduled — 2026-05-07
Apr 22, 2026
other
PMV Pharmaceuticals Announces Board Chair Transition
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair <pre>Rich Heyman to retire from
Mar 6, 2026
earnings
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
<p align="justify">PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a pr
Mar 4, 2026
earnings_calendar
PMVP Q4 2025 Earnings After Market Close — 2026-03-04
Mar 2, 2026
earnings_calendar
PMVP Q4 2025 Earnings After Market Close — 2026-03-02